Transapical transcatheter aortic valve implantation in a high-risk patient with aortic and mitral regurgitation: usage of the JenaValve™ system

Year 2016, Volume: 2 Issue: 3, 219 - 221, 04.11.2016

Suleyman Surer İlker Ince İbrahim Duvan Cengizhan Bayyurt Ugursay Kiziltepe

https://doi.org/10.18621/eurj.2016.5000197998

Abstract

JenaValve^TM system is a second-generation transcatheter heart valve that provides a successful deployment not only in calcified stenotic aortic valves but also in non-calcified, severe regurgitant aortic valves. We performed a transapical transcatheter aortic valve implantation procedure using this system without any procedure-related complications in a 75-year-old woman with multiple co-morbidity factors, who had both mitral and aortic regurgitation, and low ejection fraction. 

 

Keywords

Aortic regurgitation, mitral regurgitation, transcatheter aortic valve implantation, transapical, JenaValve™ system

References

• Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012;33:2451-96.
• Holmes DR Jr, Mack MJ, Kaul S, Agnihotri A, Alexander KP, Bailey SR, et al. 2012 ACCF/ AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol 2012;59:1200-54.
• Seiffert M, Bader R, Kappert U, Rastan A, Krapf S, Bleiziffer S, et al. Initial German experience with transapical implantation of a second-generation transcatheter heart valve for the treatment of aortic regurgitation. JACC Cardiovasc Interv 2014;7:1168-74.